Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$103.23 USD
-0.20 (-0.19%)
Updated Jun 5, 2024 04:00 PM ET
After-Market: $103.06 -0.17 (-0.16%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
Brokerage Reports
0 items in cart
Abbott Laboratories [ABT]
Reports for Purchase
Showing records 421 - 440 ( 527 total )
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Well positioned to consistently deliver doubledigit earnings growth over the next few years
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Zacks Earnings Trends: Will Earnings Growth Bottom in Q2? Companies mentioned- FDX, ORCL, PFE, ABT, MRK, DRI, WAG, AAPL
Provider: ZACKS INVESTMENT RESEARCH
Analyst: MIAN S
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Emerging Markets Play: 40% of sales
Provider: G.RESEARCH, LLC
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Former Abbott Issues Final Financial Report. New Abbott Issues 2013 Outlook
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
When-Issued Trading Begins in Separate Publicly- Traded Units. Ratings Assigned to Split Companies.
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S